Sarepta Therapeutics Inc
NASDAQ: SRPT
$126.66
-$2.14 (-1.7%)
Closing price April 30, 2024
The top analyst upgrades, downgrades and other research calls from Friday included AMC, Alkermes, Echostar, Kohls, L Brands, US Bancorp and Sarepta Therapeutics.
Published:
Last Updated:
These four top Suntrust biotech picks for 2018 all have the potential for big upside moves if they do indeed exceed first-quarter expectations.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Tuesday include AMD, Altice, Century Aluminum, Cerner, Chipotle, Cigna, GE, Micron and Noble Energy.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Friday include BioMarin, CSX, Kinder Morgan, Microsemi, Splunk, U.S. Steel and Walmart.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Wednesday include Callaway Golf, Capital One, Sarepta Therapeutics, Tesla, UnitedHealth and Wayfair.
Published:
Last Updated:
A new RBC report is reasonably positive on the biotech sector for the coming year. These eight top picks for 2018 all have the potential for big upside moves.
Published:
Sarepta Therapeutics saw its shares hit a new multiyear high on Friday after the firm announced that it received a key approval from the FDA.
Published:
Last Updated:
Amicus Therapeutics is another biotech player seeing a nice boost from the World Muscle Society Conference in France.
Published:
Last Updated:
Catabasis Pharmaceuticals shares continued their incredible climb after the announcement of positive efficacy results from its MoveDMD trial in a late-breaking session at the World Muscle Society...
Published:
Last Updated:
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) saw its shares make a handy gain on Monday after the firm received an upgrade from Morgan Stanley. The driving force behind this upgrade is Sarepta’s...
Published:
Last Updated:
Source: courtesy of Jon OggStocks were indicated to open higher on Monday after hitting all-time highs the prior week. The one trend that has been proven time after time in this eight-year bull...
Published:
Last Updated:
24/7 Wall St. has collected several catalysts that are coming up in October for biotech and pharmaceutical companies.
Published:
Sarepta Therapeutics saw its shares make a handy gain on Wednesday after the firm announced muscle biopsy results from its mid-stage study for the treatment of Duchenne muscular dystrophy.
Published:
Last Updated:
Wednesday’s top analyst upgrades, downgrades and initiations included AstraZeneca, Hasbro, Roche, Peabody Energy, Suncor and Wynn Resorts,
Published:
Last Updated:
A recent research report from the biotech team at Baird offers their top picks for 2017. While hardly pounding the table, they are cautiously optimistic on the industry.
Published:
Last Updated: